UPLIZNA Drug Profile

✉ Email this page to a colleague

Summary for Tradename: UPLIZNA

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for UPLIZNA

Recent Clinical Trials for UPLIZNA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Amgen	Phase 4

See all UPLIZNA clinical trials

Pharmacology for UPLIZNA

Mechanism of Action	CD19-directed Antibody Interactions
Established Pharmacologic Class	CD19-directed Cytolytic Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for UPLIZNA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for UPLIZNA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for UPLIZNA Derived from Patent Text Search

No patents found based on company disclosures

UPLIZNA Market Dynamics, Revenue Trajectory, Patent Risk, and Competitive Outlook

Last updated: September 7, 2026

UPLIZNA, or inebilizumab-cdon, is a CD19-directed B-cell-depleting antibody marketed by Amgen after its acquisition of Horizon Therapeutics. The drug was first approved in the United States in 2020 for adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder, or AQP4-IgG-positive NMOSD. Its commercial outlook depends on three factors: expansion into additional autoimmune diseases, conversion of patients from chronic infusion and immunosuppressive therapies, and the durability of its patent and regulatory exclusivity position.

NMOSD creates a high-value but relatively small initial market. UPLIZNA’s larger growth opportunity is IgG4-related disease and other B-cell-mediated autoimmune conditions. Before any major label expansion, UPLIZNA had established a commercial base but remained substantially smaller than the leading autoimmune biologics marketed by Amgen and its competitors.

What is UPLIZNA and how does its mechanism affect the market?

UPLIZNA is a humanized monoclonal antibody that binds CD19 on B cells and produces B-cell depletion. The mechanism differs from CD20-directed therapies such as rituximab, ocrelizumab and ofatumumab because CD19 is expressed across a broader range of B-cell development stages, including plasmablasts.

The FDA-approved NMOSD indication requires patients to test positive for AQP4-IgG. The product is administered intravenously, with an initial loading regimen followed by maintenance dosing every six months. That schedule supports adherence and reduces treatment frequency relative to daily oral immunosuppression.

Attribute	UPLIZNA
Active ingredient	Inebilizumab-cdon
Manufacturer	Amgen
Original developer	Viela Bio
Target	CD19
Initial U.S. approval	June 11, 2020
Initial indication	AQP4-IgG-positive NMOSD in adults
Route	Intravenous infusion
Maintenance frequency	Generally every six months
Core competitors	Soliris, Ultomiris, Enspryng, rituximab, immunosuppressive therapies

The commercial advantage is the prevention of NMOSD attacks rather than symptomatic treatment after relapse. The economic value is therefore tied to avoided disability, hospitalization and long-term neurological care.

How large is the UPLIZNA market?

The initial NMOSD market is limited by disease prevalence and the requirement for AQP4-IgG positivity. Industry estimates generally place the global NMOSD population in the tens of thousands, with the United States representing a smaller treated population. The addressable market is narrower than for multiple sclerosis, rheumatoid arthritis or generalized myasthenia gravis.

UPLIZNA competes in a specialty market with high treatment costs and concentrated prescribing among neurologists. The principal market segments are:

Newly diagnosed AQP4-IgG-positive patients.
Patients switching from rituximab or other off-label B-cell therapies.
Patients with breakthrough attacks on existing biologics.
Patients seeking twice-yearly maintenance dosing.
International patients gaining access through reimbursement or hospital channels.

The competitive environment includes AstraZeneca’s Soliris and Ultomiris, Roche’s Enspryng and off-label rituximab. Ultomiris has a longer-acting complement-inhibition profile, while Enspryng is a subcutaneous interleukin-6 receptor therapy. UPLIZNA’s differentiation is B-cell depletion, intravenous administration and six-month maintenance dosing.

What has UPLIZNA’s revenue trajectory been?

Horizon’s commercial disclosures showed rapid growth from a low launch base, although UPLIZNA remained a specialty product compared with Horizon’s larger medicines. Publicly reported sales increased materially after the initial launch period as the company expanded diagnosis, reimbursement and physician adoption.

Period	Commercial development	Financial interpretation
2020	U.S. launch for AQP4-IgG-positive NMOSD	Limited launch-period revenue
2021	Early commercial expansion	Revenue moved into the tens of millions
2022	Broader neurologist adoption and international activity	Revenue reached the low hundreds of millions
2023	Continued NMOSD growth under Horizon	Product became a meaningful Horizon growth asset
2024 onward	Amgen ownership and label-expansion strategy	Valuation increasingly linked to new indications

Horizon reported UPLIZNA net sales of approximately $29 million in 2021 and more than $100 million in 2022. The exact annual figures vary by reporting period and presentation, but the direction was consistent: strong percentage growth from a small base, followed by increasing dependence on label expansion to sustain a high-growth profile (Horizon Therapeutics, 2023).

The acquisition of Horizon gave Amgen access to UPLIZNA alongside Tepezza and Krystexxa. Amgen’s strategic rationale was not limited to existing NMOSD sales. The value case included commercial infrastructure, specialty prescriber access and the possibility of expanding inebilizumab into diseases with substantially larger treated populations.

What is the next major growth opportunity for UPLIZNA?

IgG4-related disease is the most important expansion opportunity. It is a chronic immune-mediated condition that can affect the pancreas, salivary glands, lymph nodes, kidneys, retroperitoneum and other organs. Treatment often relies on corticosteroids and immunosuppressants, with substantial relapse and organ-damage risk.

A successful IgG4-related disease indication would expand UPLIZNA from a rare neuroimmunology product into a broader autoimmune therapy. The market could support higher patient volumes and longer treatment duration than NMOSD, although payer controls and competition from off-label rituximab would remain significant.

Other potential development areas include:

Generalized myasthenia gravis.
Autoimmune encephalitis.
Multiple sclerosis-related B-cell disease.
Other antibody-mediated neurological disorders.
Additional systemic autoimmune diseases.

The commercial quality of these opportunities depends on trial outcomes, biomarker selection and the ability to demonstrate superiority or meaningful differentiation against low-cost rituximab.

How does UPLIZNA compare with competing biologics?

Product	Mechanism	Administration	Commercial strength	UPLIZNA competitive response
UPLIZNA	CD19 B-cell depletion	Intravenous, approximately twice yearly maintenance	Differentiated mechanism and dosing convenience	Requires infusion access and monitoring
Ultomiris	C5 complement inhibition	Intravenous or subcutaneous depending on indication	Strong rare-disease infrastructure	Competes for NMOSD patients with established therapy
Soliris	C5 complement inhibition	Intravenous	Mature NMOSD franchise	Longer market history but shorter dosing intervals
Enspryng	IL-6 receptor inhibition	Subcutaneous	At-home administration	More convenient route for some patients
Rituximab	CD20 B-cell depletion	Intravenous	Low-cost, widely used off label	Major price and physician-familiarity threat

UPLIZNA has the strongest strategic position when physicians value durable B-cell depletion and a twice-yearly dosing schedule. Its main weakness is that it competes against rituximab, which is inexpensive and widely understood, even though rituximab may be used off label and has a different target.

What patents protect UPLIZNA?

UPLIZNA’s protection is expected to include biologic composition claims, antibody sequence claims, therapeutic-use claims, dosing claims and manufacturing-related intellectual property. The most commercially relevant claims are those covering the inebilizumab antibody and its use in NMOSD or other autoimmune diseases.

Biologic patent risk differs from conventional small-molecule generic risk. A competing manufacturer cannot normally rely on an ANDA pathway alone. A biosimilar sponsor must establish high similarity and interchangeability, where applicable, under the Biologics Price Competition and Innovation Act.

The key protection categories are:

Antibody and sequence claims covering inebilizumab.
CD19-directed treatment claims.
NMOSD treatment and relapse-prevention claims.
Patient-selection claims involving AQP4-IgG status.
Dosing and administration claims.
Formulation and stability claims.
Manufacturing and cell-line claims.

Public FDA biologics records and Orange Book treatment must be distinguished. FDA’s Orange Book primarily lists approved small-molecule drug products and does not function as a complete patent register for biologics. UPLIZNA’s biologic exclusivity and patent information must therefore be assessed through FDA biologics records, USPTO data, court filings and Amgen’s regulatory disclosures rather than an Orange Book entry alone (FDA, 2020; USPTO, 2024).

When does UPLIZNA lose exclusivity?

UPLIZNA received 12 years of U.S. reference-product exclusivity as a biologic, subject to statutory rules governing biosimilar applications and approval. Based solely on the June 2020 approval date, the statutory reference-product exclusivity period would extend into 2032.

Patent expiry may occur before or after the end of regulatory exclusivity. The effective biosimilar entry date will depend on:

The expiration of relevant composition and use patents.
Whether a biosimilar sponsor initiates the patent dance.
Patent litigation under the BPCIA.
Settlement terms.
FDA approval timing.
Pediatric exclusivity or other applicable extensions.

The practical entry risk before 2032 is lower than for a conventional small molecule because biosimilar development is costly, clinical comparability requirements are substantial and the initial NMOSD market is relatively small.

Are biosimilars or Paragraph IV challenges a near-term risk?

A traditional Paragraph IV ANDA challenge is not the normal route for UPLIZNA because it is a biologic. Biosimilar applicants may challenge relevant patents through the BPCIA framework rather than filing a standard ANDA Paragraph IV certification.

Near-term biosimilar risk is limited by market size and manufacturing complexity. CD19 antibody production requires validated cell lines, process controls, analytical comparability and clinical or pharmacological evidence sufficient for FDA review. A biosimilar sponsor would also face payer and physician switching barriers in a rare neurological disease.

The higher near-term risk is therapeutic substitution from existing biologics, especially rituximab and newer agents, rather than direct biosimilar erosion.

What FDA and regulatory factors affect UPLIZNA revenue?

The main regulatory value driver is label expansion. New approvals can increase the treated population, improve payer coverage and reduce dependence on NMOSD diagnosis rates.

Important regulatory factors include:

Confirmatory and expansion-trial outcomes.
The strength of relapse-reduction data.
Organ-protection evidence in systemic autoimmune disease.
Safety monitoring for infections and hypogammaglobulinemia.
Infusion-related reactions.
Vaccine response and immunoglobulin management.
Label language concerning pregnancy and reproductive risk.
Postmarketing obligations.

Regulators and payers will evaluate whether the benefits of CD19 depletion justify the cost and monitoring burden relative to rituximab and other established immunotherapies.

What licensing deals and corporate transactions affect UPLIZNA?

Viela Bio developed UPLIZNA and commercialized it before Horizon acquired Viela in 2021. Amgen then acquired Horizon in 2023 for approximately $27.8 billion. The transaction transferred UPLIZNA, Tepezza and Krystexxa to Amgen (Amgen, 2023).

The transaction changed UPLIZNA’s commercial trajectory in three ways:

It added Amgen’s global regulatory and commercial infrastructure.
It increased the probability of development in additional autoimmune diseases.
It shifted investor focus from standalone product growth to portfolio-level return on acquisition capital.

UPLIZNA must now generate growth that supports the purchase price allocation and offsets future competition to Horizon’s established products.

What generic launch scenarios exist for UPLIZNA?

Scenario	Timing	Market effect
Base case	Before broad biosimilar activity	Continued growth driven by NMOSD and selected label expansions
Expansion case	New indications succeed	Revenue can move from niche-product scale toward blockbuster potential
Competitive case	Rituximab and rival biologics gain share	Price concessions and slower patient additions
Erosion case	Biosimilar entry follows patent and exclusivity expiry	Rapid payer-driven substitution is possible
Failure case	Expansion trials disappoint	UPLIZNA remains dependent on a limited NMOSD population

The most likely commercial path before biologic exclusivity expiry is gradual expansion rather than abrupt generic erosion. Revenue concentration will remain high because the product depends on a small number of specialty indications and prescriber networks.

How strong is the UPLIZNA commercial and patent estate?

UPLIZNA has a strong regulatory position in NMOSD and a credible mechanism-based differentiation. Its patent position is more difficult to assess from public summary data than its FDA approval status because biologic protection is distributed across multiple patent and regulatory instruments.

The estate is commercially stronger if Amgen secures additional method-of-use patents covering new diseases, dosing schedules and biomarker-defined populations. Those claims could extend practical protection beyond the original NMOSD market and make biosimilar substitution more difficult across indications.

Its principal vulnerabilities are:

Small initial patient population.
Off-label rituximab pricing pressure.
Infusion-center dependence.
Safety and immunoglobulin-monitoring requirements.
Dependence on successful indication expansion.
Potential payer preference for subcutaneous competitors.

Key Takeaways

UPLIZNA is a CD19-directed biologic approved initially for AQP4-IgG-positive NMOSD.
Its initial market is commercially attractive but numerically small.
Revenue grew rapidly from launch, reaching more than $100 million annually during Horizon’s ownership.
Amgen’s acquisition of Horizon increased the value of label expansion and global commercialization.
IgG4-related disease is the most important potential growth market.
Rituximab is the main economic competitor because of its low cost and broad physician familiarity.
UPLIZNA is not exposed to a conventional small-molecule Paragraph IV pathway.
Biologic exclusivity extends into the early 2030s based on the 2020 approval date, while patent expiry dates must be assessed separately.
Manufacturing complexity and a limited initial market reduce near-term biosimilar risk.
Long-term valuation depends more on clinical expansion than on NMOSD alone.

FAQs

Is UPLIZNA a blockbuster drug?

UPLIZNA had not reached blockbuster scale based on publicly reported early commercial sales. It could approach blockbuster potential if it succeeds in larger autoimmune indications such as IgG4-related disease.

Is UPLIZNA better than rituximab?

UPLIZNA has a different target, CD19, and a defined FDA-approved NMOSD indication. Rituximab is less expensive and widely used off label. Clinical and economic superiority depends on the disease, patient profile and payer policy.

Can UPLIZNA be substituted with a biosimilar?

A biosimilar may eventually be approved, but substitution depends on FDA interchangeability status, state law, payer policy and physician acceptance. UPLIZNA’s biologic exclusivity and patent position delay ordinary generic substitution.

What is the biggest risk to UPLIZNA revenue?

The largest risk is failure to expand beyond NMOSD. The current indication supports a specialty commercial franchise, but sustained high growth requires new diseases, broader reimbursement and continued differentiation from rituximab.

Who owns the UPLIZNA patents?

Amgen owns the UPLIZNA business through its acquisition of Horizon Therapeutics, which previously acquired Viela Bio. Patent ownership and licensing rights should be confirmed against individual USPTO records and transaction documents.

References

Amgen Inc. (2023). Amgen completes acquisition of Horizon Therapeutics. https://www.amgen.com

Food and Drug Administration. (2020). FDA approves new treatment for neuromyelitis optica spectrum disorder. https://www.fda.gov

Horizon Therapeutics plc. (2023). Annual report and Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov

U.S. Patent and Trademark Office. (2024). Patent Center and patent examination resources. https://www.uspto.gov

More… ↓

⤷ Start Trial